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OBJECTIVES: Diabetes is a serious, costly metabolic disorder with a rising preva-
lence worldwide. Chromium has long been shown to improve insulin sensitivity,
lipid profiles, and blood glucose in insulin resistance and type-2 diabetic patients.
METHODS: All relevant databases were searched up to December 2011 limited to
human studies in English language. Clinical studies in newly onset patients with
type-2 diabetes reporting use of chromium at least for 4 weeks and outcomes of
fasting blood glucose (FBG), hemoglobin A1C (HbA1c), triglyceride (TG), low density
lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL) and body
mass index (BMI) were identified. Data of before and after use of chromium intake
were compared. RESULTS: The functional outcome data from clinical studies re-
vealed that our of 834 studies, 39 met inclusion criteria. Seventy present of articles
demonstrated a decrease in FBS while 23% showed an increase. Forty-seven per-
cent of studies showed an increase in HbA1c, while 15% a decrease. TG in 60% of
studies showed an increase while in 15% a reductionwas reported. LDL cholesterol
in 60% of studies showed a decrease and in the rest there was no report of increase.
Forty percent of studies showed a decrease in HDL cholesterol while 30% showed
an increase. BMI in 40% of studies decreased and in 7% of cases increased.
CONCLUSIONS: In clinical studies, average of mentioned parameters were im-
proved significantly after administration of chromium in patients with type 2 dia-
betes in a dose-dependent manner with no side effects. This systematic review
indicates beneficial effects of chromium in diabetic patients.
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OBJECTIVES: Growing rates of obesity and type 2 diabetes mellitus (T2DM) are
major health problems in China. Bariatric surgery is an effective treatment for
patientswith clinically severe obesity additionally improving co-morbidities, while
metabolic surgery is a procedure aimed at resolution of T2DM. The main objective
of our study was to assess the efficacy of both procedures performed on Chinese
population. METHODS: A comprehensive search was performed in PUBMED and
websites of Chinesemedical databases and journals including: www.wanfangdata.
com, www.cqvip.com, www.cnki.net, www.docin.com, wenku.baidu.com. Studies
met the inclusion criteria if they enrolled obese Chinese patients with or without
T2DM undergoing following laparoscopic procedures: sleeve gastrectomy, Roux-
en-Y gastric bypass, adjustable gastric banding, single-incision sleeve gastrectomy.
RESULTS:Our search retrieved 17 studies (2339 patients) of which 7 included T2DM
patients (N  374) exclusively. Overall, mean BMI reduction one year following
surgery ranged from 5.7 to 16.8 kg/m2. Excessive weight loss ranged between 25.4-
81.25% and 18.4-72.2%, after 1st and 2nd year of follow-up, respectively. Moreover, 2
years following surgery hypertension resolved in 9-98% of patients, hyperlipidemia
in 42-100%, arthralgia in 90% and sleep apnea in 68-100%. In the subset of diabetes
patients resolution of T2DM was observed in 33%-93% individuals 1 year post-
surgery. In the same timemean HbA1c was improved by 1.2-4.4 percentage points,
FBG was reduced by 37.8-107.2 mg/dl and BMI declined by 5.7-7.1 kg/m2. Bariatric
procedures led to complication rates ranging from 0 to 23.5% during the first post-
operative year and from 5 to 57% during the second year. Reported mortality was
low and did not exceed 0.47%. Additionally, surgery had beneficial effect on pa-
tients’ quality of life, which improved especially in physical, emotional and social
domains. CONCLUSIONS: Bariatric surgery is effective in achieving durable weight
loss and as well as improvement or resolution of T2DM and other co-morbidities.
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OBJECTIVES: Hypertension and obesity are associated with long-term complica-
tions of type 2 diabetes mellitus (T2DM). A systematic literature review assessed
the prevalence of these comorbidities in adults with T2DM in Asia. METHODS:
Electronic databases (PubMed, Embase, Cochrane Library) were searched for pub-
lications related to T2DM plus hypertension and/or obesity (English, 2001-2011).
Bibliographies of included studies were also examined. RESULTS:Of 2303 abstracts
identified, 38 observational studies presented relevant data across 14 countries/
regions in Asia. Prevalence rates reported here are for adults with T2DM. In China,
hypertension prevalence was 49.9%-60.6% when hypertension was defined by
blood pressure cutpoints of 140/90 mmHg and/or use of antihypertensive medi-
cine,whereas the prevalencewas 74.7%-76.5%whenblood pressure cutpointswere
reduced to 130/85. A study in Israel using cutpoints of 140/90, 130/85, and
130/80 mmHg found hypertension prevalence rates of 60.2%, 76.5%, and 85.8%,
respectively. In studies reporting prevalence by a single hypertension definition,
the prevalence rates ranged from 61.0% to 78.1% when the cutpoints were130/80
or 130/85 mmHg and 13.6% to 78.4% when the cutpoints were 140/90 mmHg.
Obesity prevalence data were limited. Cutpoints for defining obesity by body mass
index (BMI) or waist circumference (WC) varied among the studies. The obesity
prevalence rates by BMI were: Israel, 20.1%; Japan, 33.9%; Qatar, 53.8%; Taiwan,
38%-52.7%; Jordan, 58.6%; Saudi Arabia, 83.4%; Iran, 85.5%; and byWCwere: Japan,
24.3%-27.0%; South Korea, 37.2%; Pakistan, 61.5%; India, 67%. Few studies reported
comorbidity of both hypertension and obesity, with varying definitions of each
comorbidity. The prevalence of hypertension with obesity was: Saudi Arabia,
10.7%; Japan, 18.0%-20.6%; Jordan, 76.6%; Israel, 69.7%-93.3%. CONCLUSIONS: In
Asians, hypertension and obesity, separately or together, are common comorbidi-
ties of T2DM. Accurate, consistent reporting of their prevalence will help quantify
efforts needed to manage these comorbidities and their long-term health and cost
consequences.
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OBJECTIVES:The association of A1C’s variabilitywith developing newdiabetes has
been little studied. We aimed to evaluate the effect of visit-to-visit A1C variability
on the risk of developing new diabetes in healthy adults in Japan. METHODS:
Population-based, cohort study from 2005 to 2008 in Tokyo, Japan of healthy adults
not taking diabetes medication and with a HbA1c lower than 6.5% at baseline.
Based on annual measurement of serum HbA1c we calculated the annual visit-to-
visit variability, and used this as a predictor of new onset diabetes in amultivariate
logistic regression. RESULTS: At baseline, 14,587 people (50% female) with a mean
age of 51 years old (SD: 12 years, range: 23 to 92), a mean fasting plasma glucose
(FPG) level of 98.4 mg/dl (SD: 9.3 mg/dl) and a mean HbA1c level of 5.3 % (SD: 0.4 %)
had annual check-ups over 4 years. After adjusting for the other potential risk
factors new diabetes was predicted by the A1C variability (odds ratio (OR): 10.3 for
highest ( 0.16%)) versus the lowest quantile (0.08 %), 95%CI: 5.9 – 18.0) and by
the baseline A1C (OR: 55.2 for A1C of 6.0 – 6.4 % versus A1C of 5.0 %, 95% CI: 13.2
– 230). FPG (OR: 1.1, 95%CI: 1.1 – 1.2) and Smoker (OR: 1.8, 95%CO: 1.3 – 2.6) weakly
but also significantly related to develop the new diabetes. For predicting the devel-
opment of diabetes, the combination of the level of AIC at baseline and the vari-
ability (AUC for the ROC0.94) was superior to the level of A1C at baseline alone
(AUC0.89). CONCLUSIONS: Visit-to-visit variability in A1C independently added
to the baselineA1C in predicting the risk of developing newdiabetes for the healthy
adults. We should consider not only the baseline A1c level but also variability in
A1C to prevent development of the diabetes.
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OBJECTIVES:The FDAwarned on June 15, 2011 of the bladder cancer risk associated
with pioglitazone use. Therefore, we conducted a retrospective review of pioglita-
zone use in our hospital, to find out high risk patient, provide FDA safety advice by
using electronic message in computerized physician order entry system (CPOE),
aim to ensure physician aware of the risk at the moment of patient clinic visit.
METHODS: We included outpatients with pioglitazone use from January 1, 2006
through July 31, 2011. For high risk patients, who are male, prescribed pioglitazone
more than 1 year and cumulative dose reached 28000mg, clinical pharmacists will
established warning message in CPOE. The message was to inform physician the
patient was at high risk for bladder cancer, and should care about the symptoms of
bladder cancer, such as hematuria; urgent need to urinate or pain while urinating;
pain in back or lower abdomen. RESULTS: Overall 3196 patients had ever pre-
scribed pioglitazone. The mean age was 63.2  11.9 years, and 1519 (49%) of the
patients were male. Five (0.16%) patients with the diagnosis of bladder cancer.
There were 1874 patients with currently pioglitazone use, 629 (33.5%) patients pre-
scribed pioglitazonemore than 1 year, 160 (8.5%) patients cumulative dose reached
28000mg, and 75 (4%) of our patients were at high risk for bladder cancer. Eighteen
(24%) high risk patients were discontinued pioglitazone after FDA announcement,
another 18 (24%) patients because ofwarningmessage established by clinical phar-
macists. Twenty six (66.7%) patients have urine test, 5 (12.8%) with positive occult
blood. CONCLUSIONS: From the retrospective results, there was no association
between pioglitazone use and bladder cancer in our hospital. The communication
by using electronicmessage in CPOE enhanced the awareness of physician. Clinical
pharmacistswill prospectively establish thewarningmessage for patientwith high
risk.
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OBJECTIVES: To compare diabetes-related complications, utilizations and costs
between diabetes patients treated with DPP4i-based combinations (DPP4iMET or
DPP4iPIO) vs. SU-based combinations (SUMET or SUPIO).METHODS: Market-
Scan, a U.S. database of insured members, was analyzed to retrospectively com-
pare outcomes between patients treated with DPP4i and SU combinations. The
study sample consisted of T2DM patients who received DPP4i or SU combinations
and had continuous eligibility from 6months prior to and 12months following the
index date (date of combination therapy initiation). Rates of diabetic complica-
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